BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

94 related articles for article (PubMed ID: 18419622)

  • 1. Genes associated with the tumour microenvironment are differentially expressed in cured versus primary chemotherapy-refractory diffuse large B-cell lymphoma.
    Linderoth J; Edén P; Ehinger M; Valcich J; Jerkeman M; Bendahl PO; Berglund M; Enblad G; Erlanson M; Roos G; Cavallin-Ståhl E
    Br J Haematol; 2008 May; 141(4):423-32. PubMed ID: 18419622
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Expression of TNF-receptor associated factor 2 correlates with poor progression-free survival time in ABC-like primary nodal diffuse large B-cell lymphomas.
    van Galen JC; Muris JJ; Giroth CP; Vos W; Ossenkoppele GJ; Meijer CJ; Oudejans JJ
    Histopathology; 2008 Apr; 52(5):578-84. PubMed ID: 18312353
    [TBL] [Abstract][Full Text] [Related]  

  • 3. An expression signature classifies chemotherapy-resistant pediatric osteosarcoma.
    Mintz MB; Sowers R; Brown KM; Hilmer SC; Mazza B; Huvos AG; Meyers PA; Lafleur B; McDonough WS; Henry MM; Ramsey KE; Antonescu CR; Chen W; Healey JH; Daluski A; Berens ME; Macdonald TJ; Gorlick R; Stephan DA
    Cancer Res; 2005 Mar; 65(5):1748-54. PubMed ID: 15753370
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Expression of a soluble decoy receptor 3 in patients with diffuse large B-cell lymphoma predicts clinical outcome.
    Chang PM; Chen PM; Hsieh SL; Tzeng CH; Liu JH; Chiou TJ; Wang WS; Yen CC; Gau JP; Yang MH
    Int J Oncol; 2008 Sep; 33(3):549-54. PubMed ID: 18695885
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Profiling of apoptosis genes allows for clinical stratification of primary nodal diffuse large B-cell lymphomas.
    Muris JJ; Ylstra B; Cillessen SA; Ossenkoppele GJ; Kluin-Nelemans JC; Eijk PP; Nota B; Tijssen M; de Boer WP; van de Wiel M; van den Ijssel PR; Jansen P; de Bruin PC; van Krieken JH; Meijer GA; Meijer CJ; Oudejans JJ
    Br J Haematol; 2007 Jan; 136(1):38-47. PubMed ID: 17062006
    [TBL] [Abstract][Full Text] [Related]  

  • 6. National Oncology Forum: perspectives for the year 2000.
    DeVita VT; Bleickardt EW
    Cancer J; 2001; 7 Suppl 1():S2-13. PubMed ID: 11504281
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Gene expression profiles of Hodgkin's lymphoma cell lines with different sensitivity to cytotoxic drugs.
    Staege MS; Banning-Eichenseer U; Weissflog G; Volkmer I; Burdach S; Richter G; Mauz-Körholz C; Föll J; Körholz D
    Exp Hematol; 2008 Jul; 36(7):886-96. PubMed ID: 18400362
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inhibition of the intrinsic apoptosis pathway downstream of caspase-9 activation causes chemotherapy resistance in diffuse large B-cell lymphoma.
    Cillessen SA; Hess CJ; Hooijberg E; Castricum KC; Kortman P; Denkers F; Vos W; van de Wiel MA; Schuurhuis GJ; Ossenkoppele GJ; Meijer CJ; Oudejans JJ
    Clin Cancer Res; 2007 Dec; 13(23):7012-21. PubMed ID: 18056177
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Psoralen plus ultraviolet A +/- interferon-alpha treatment resistance in mycosis fungoides: the role of tumour microenvironment, nuclear transcription factor-kappaB and T-cell receptor pathways.
    Wozniak MB; Tracey L; Ortiz-Romero PL; Montes S; Alvarez M; Fraga J; Fernández Herrera J; Vidal S; Rodriguez-Peralto JL; Piris MA; Villuendas Deceased R
    Br J Dermatol; 2009 Jan; 160(1):92-102. PubMed ID: 18945306
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Molecular targeted therapies for diffuse large B-cell lymphoma based on apoptosis profiles.
    Cillessen SA; Meijer CJ; Notoya M; Ossenkoppele GJ; Oudejans JJ
    J Pathol; 2010 Apr; 220(5):509-20. PubMed ID: 20087881
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Presence of a high-grade component in gastric mucosa-associated lymphoid tissue (MALT) lymphoma is not associated with an adverse prognosis.
    Ang MK; Hee SW; Quek R; Yap SP; Loong S; Tan L; Tao M; Lim ST
    Ann Hematol; 2009 May; 88(5):417-24. PubMed ID: 18777110
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Addition of rituximab to standard chemotherapy improves the survival of both the germinal center B-cell-like and non-germinal center B-cell-like subtypes of diffuse large B-cell lymphoma.
    Fu K; Weisenburger DD; Choi WW; Perry KD; Smith LM; Shi X; Hans CP; Greiner TC; Bierman PJ; Bociek RG; Armitage JO; Chan WC; Vose JM
    J Clin Oncol; 2008 Oct; 26(28):4587-94. PubMed ID: 18662967
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Profiling of apoptosis genes identifies distinct types of primary cutaneous large B cell lymphoma.
    van Galen JC; Hoefnagel JJ; Vermeer MH; Willemze R; Dijkman R; Tensen CP; de Boer WP; Meijer CJ; Oudejans JJ
    J Pathol; 2008 Jul; 215(3):340-6. PubMed ID: 18498125
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Interaction between BCL2 and interleukin-10 gene polymorphisms alter outcomes of diffuse large B-cell lymphoma following rituximab plus CHOP chemotherapy.
    Park YH; Sohn SK; Kim JG; Lee MH; Song HS; Kim MK; Jung JS; Lee JJ; Kim HJ; Kim DH
    Clin Cancer Res; 2009 Mar; 15(6):2107-15. PubMed ID: 19276283
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Drug resistance in diffuse large B-cell lymphoma.
    Wilson WH
    Semin Hematol; 2006 Oct; 43(4):230-9. PubMed ID: 17027657
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mutation or polymorphism of the CD20 gene is not associated with the response to R-CHOP in diffuse large B cell lymphoma patients.
    Sar A; Perizzolo M; Stewart D; Mansoor A; Difrancesco LM; Demetrick DJ
    Leuk Res; 2009 Jun; 33(6):792-7. PubMed ID: 19054557
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Molecular diagnosis of lymphoma: outcome prediction by gene expression profiling in diffuse large B-cell lymphoma.
    Last K; Debarnardi S; Lister TA
    Methods Mol Med; 2005; 115():15-63. PubMed ID: 15998962
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Genomic alterations and gene expression in primary diffuse large B-cell lymphomas of immune-privileged sites: the importance of apoptosis and immunomodulatory pathways.
    Booman M; Szuhai K; Rosenwald A; Hartmann E; Kluin-Nelemans H; de Jong D; Schuuring E; Kluin P
    J Pathol; 2008 Oct; 216(2):209-17. PubMed ID: 18729069
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Increased serum 90K and Galectin-3 expression are associated with advanced stage and a worse prognosis in diffuse large B-cell lymphomas.
    Kim SJ; Lee SJ; Sung HJ; Choi IK; Choi CW; Kim BS; Kim JS; Yu W; Hwang HS; Kim IS
    Acta Haematol; 2008; 120(4):211-6. PubMed ID: 19153476
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Rituximab improves the efficacy of high-dose chemotherapy with autograft for high-risk follicular and diffuse large B-cell lymphoma: a multicenter Gruppo Italiano Terapie Innnovative nei linfomi survey.
    Tarella C; Zanni M; Magni M; Benedetti F; Patti C; Barbui T; Pileri A; Boccadoro M; Ciceri F; Gallamini A; Cortelazzo S; Majolino I; Mirto S; Corradini P; Passera R; Pizzolo G; Gianni AM; Rambaldi A
    J Clin Oncol; 2008 Jul; 26(19):3166-75. PubMed ID: 18490650
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.